Recently, GPNMB was shown to promote the toxic aggregation of the alpha-synuclein protein in substantia nigra, which is believed to contribute to neurodegeneration, and could be a potential target for PD treatment (24, 32). The gene discussed is GPNMB; the disease is Parkinson disease.